MRK — Merck & Co., Inc. stock price, charts and financials

QT64Merck & Co., Inc.

Merck & Co., Inc. (NYSE: MRK) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
147.60
-0.86-0.58%
OverviewShort InterestFilings
MRKQT64Merck & Co., Inc.·NYSE
147.60-0.58%
News
Down 0.6% — Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ABBV+0.86%$250.91NVS-0.16%$137.48AZN-1.94%$156.94AMGN-0.48%$391.27JNJ-0.76%$267.08NVO-1.33%$44.56GILD-0.68%$145.65PFE-0.04%$27.78
Snapshot
IndexS&P 500, DJIAP/E118.08EPS (ttm)1.25Insider Own0.09%Shs Outstand2.47BPerf Week-1.51%
Market Cap364.55BForward P/E15.46EPS next Y9.55Insider Trans-8.62%Shs Float2.47BPerf Month12.74%
Enterprise Value411.31BPEG3.08EPS next Q2.22Inst Own76.71%Short Float0.99%Perf Quarter23.41%
Income3.17BP/S5.49EPS this Y119.93%Inst Trans0.00%Short Ratio2.40Perf Half Y26.06%
Sales66.40BP/B8.68EPS next Y247.24%ROA2.44%Short Interest24.51MPerf YTD40.22%
Book/sh17.00P/C51.05EPS next 5Y38.38%ROE6.60%52W High156.92 -5.94%Perf Year75.53%
Cash/sh2.89P/FCF23.12EPS past 3/5Y8.43% 21.23%ROIC5.62%52W Low77.58 90.26%Perf 3Y34.38%
Dividend Est.3.40 (2.30%)EV/EBITDA29.71Sales past 3/5Y3.08% 9.35%Gross Margin75.38%Volatility1.90% 2.49%Perf 5Y93.47%
Dividend TTM3.36 (2.28%)EV/Sales6.19EPS Y/Y TTM-81.45%Oper. Margin16.65%ATR (14)3.85Perf 10Y145.67%
Dividend Ex-DateSep 15, 2026Quick Ratio1.10Sales Y/Y TTM3.48%Profit Margin4.78%RSI (14)56.99Recom2.35
Dividend Gr. 3/5Y5.42% 6.75%Current Ratio1.32EPS Q/Q-106.10%SMA200.57%Beta0.21Target Price158.06
Payout261.52%Debt/Eq0.96Sales Q/Q5.11%SMA509.05%Rel Volume0.74Prev Close148.46
Employees74,000LT Debt/Eq0.90EarningsOct 29SMA20024.11%Avg Volume10.49MPrice147.60
IPO DateJan 13, 1978Option/ShortYes / YesEPS/Sales Surpr.51.94% 1.45%Net Debt/EBITDA3.40Volume7,757,964Change-0.58%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-09-26ReiteratedLeerink PartnersOutperform$127 → $161
Sep-08-26ReiteratedGuggenheimBuy$146 → $170
Sep-04-26ReiteratedWells FargoOverweight$150 → $170
Aug-25-26ReiteratedArgus ResearchBuy$145 → $170
Aug-25-26ReiteratedWolfe ResearchOutperform$135 → $180
Aug-21-26ReiteratedGoldman SachsBuy$133 → $160
Aug-20-26ReiteratedUBSBuy$130 → $150
Aug-20-26DowngradeRBC CapitalOutperform → Sector Perform$142 → $150
Aug-20-26UpgradeMorgan StanleyEqual Weight → Overweight$179
Aug-20-26ReiteratedBMO CapitalOutperform$142 → $170
Latest News· Times ET
Sep-09-26
Sep-09-2601:17PM
Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcriptseekingalpha.com
09:00AM
The Big 3: ROST, MRK, AAPLyoutube.com
07:34AM
AI & Robotics in 2026: 16 Recent Developments for Investorsetftrends.com
Sep-08-26
Sep-08-2601:08PM
Is AbbVie Stock Too Reliant On Skyrizi?Yahoo
10:59AM
Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?fool.com
10:30AM
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?fool.com
10:00AM
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profitsfool.com
05:40AM
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?zacks.com
02:45AM
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferencebusinesswire.com
Sep-06-26
Sep-06-2604:51AM
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow Itmarketbeat.com
Sep-04-26
Sep-04-2602:46PM
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Knowzacks.com
Sep-03-26
Sep-03-2612:27PM
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warninggurufocus.com
08:36AM
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?zacks.com
07:24AM
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarreuters.com
Sep-02-26
Sep-02-2608:04AM
Why Moderna's Cancer Vaccine Matters to Investorsetftrends.com
Company

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Ownership
Total institutional ownership76.71%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue66,40064,92664,168——————
Cost of Goods Sold Incl. D&A16,35018,19515,193——————
Gross Profit50,05046,73148,975——————
Selling, General and Administrative Excl. Other10,39410,73110,100——————
Research and Development28,35012,51417,938——————
Other Operating Expense2500716——————
Operating Income11,05623,48620,221——————
Interest Expense1,2631,3571,271——————
Unusual Expense
—————————
Non-Operating Income (Expense)-3,845-1,062986——————
Net Income Before Taxes5,94821,06719,936——————
Income Taxes2,7792,8042,803——————
Consolidated Net Income3,17318,25417,117——————
Net Income From Continuing Operations3,16918,26317,133——————
Net Income3,17318,25417,117——————
EPS (Recurring)1.267.306.76——————
EPS (Basic, Before Extraordinaries)1.267.306.76——————
EPS (Diluted)1.257.286.74——————
EBITDA13,84428,26225,706——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio118.0814.4614.76——————
Price To Sales Ratio5.494.063.93——————
Gross Margin75.3871.9876.32——————
Operating Margin16.6536.1731.51——————
Net Margin4.7828.1226.68——————
Shares Outstanding2,4722,5022,532——————
Market Capitalization364,867263,361251,883——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$168.28$142.65$117.02$91.40$65.77● Close Price0.00M7.71M15.42M23.13M30.84MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Guindo ChirfiEVP, Access, Policy & CommsAug 13 '26Sale135.0010,0001,350,00036,613Aug 13
Zachary JenniferEVP, General CounselAug 12 '26Sale133.4680,31510,718,49545,509Aug 13
Zachary JenniferEVP, General CounselAug 12 '26Option Exercise109.7854,9276,029,637125,824Aug 13
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 12 '26Sale131.6311,6991,539,992110,167Aug 12
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 11 '26Sale131.7612,8371,691,426121,866Aug 12
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 10 '26Sale130.4320,7842,710,951134,703Aug 12
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 06 '26Sale130.386,050788,772155,487Aug 10
Guindo ChirfiEVP, Access, Policy & CommsAug 06 '26Sale131.0015,0001,965,00046,613Aug 07
Williams David MichaelEVP,Chief Info&Digital OfficerAug 05 '26Sale128.7734,7054,468,98731,716Aug 07
Maraldo David R.EVP & Pres. MMDAug 05 '26Option Exercise82.2518,7061,538,49527,921Aug 07
Maraldo David R.EVP & Pres. MMDAug 05 '26Sale128.722,686345,73618,212Aug 07
Williams David MichaelEVP,Chief Info&Digital OfficerAug 05 '26Option Exercise74.4952,8473,936,37766,421Aug 07
Maraldo David R.EVP & Pres. MMDMay 02 '26Option Exercise112.1655261,91218,371May 05
Smart Dalton E. IIISVP Fin. - Global ControllerMay 02 '26Option Exercise112.1638342,9579,520May 05
Smart Dalton E. IIISVP Fin. - Global ControllerApr 30 '26Option Exercise110.9546451,4819,296May 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.